AUD 0.0
(0.0%)
Year | Net Income | Net Income Growth |
---|---|---|
2024 | -3.53 Million AUD | 49.88% |
2023 | -7.06 Million AUD | -4.15% |
2022 | -6.78 Million AUD | -66.88% |
2021 | -4.06 Million AUD | -47.82% |
2020 | -2.74 Million AUD | -568.21% |
2019 | -411.32 Thousand AUD | 83.53% |
2018 | -2.49 Million AUD | -136.06% |
2017 | -1.05 Million AUD | 2.12% |
2016 | -1.08 Million AUD | 87.24% |
2015 | -8.47 Million AUD | -16.21% |
2014 | -7.28 Million AUD | -106.54% |
2013 | -3.52 Million AUD | 30.92% |
2012 | -5.1 Million AUD | 31.16% |
2011 | -7.42 Million AUD | 1.51% |
2010 | -7.53 Million AUD | 13.01% |
2009 | -8.66 Million AUD | -18.28% |
2008 | -7.32 Million AUD | 0.0% |
2007 | - AUD | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q2 | -1.95 Million AUD | 0.0% |
2024 FY | -3.53 Million AUD | 49.88% |
2024 Q4 | -1.58 Million AUD | 0.0% |
2023 Q2 | -3.88 Million AUD | 0.0% |
2023 Q4 | -3.17 Million AUD | 0.0% |
2023 FY | -7.06 Million AUD | -4.15% |
2022 Q2 | -4.5 Million AUD | 0.0% |
2022 Q4 | -2.27 Million AUD | 0.0% |
2022 FY | -6.78 Million AUD | -66.88% |
2021 Q4 | -2.05 Million AUD | 0.0% |
2021 Q2 | -2 Million AUD | 0.0% |
2021 FY | -4.06 Million AUD | -47.82% |
2020 FY | -2.74 Million AUD | -568.21% |
2020 Q4 | -1.03 Million AUD | 0.0% |
2020 Q2 | -1.71 Million AUD | 0.0% |
2019 Q2 | 891.65 Thousand AUD | 0.0% |
2019 FY | -411.32 Thousand AUD | 83.53% |
2019 Q4 | -1.3 Million AUD | 0.0% |
2018 Q4 | -1.5 Million AUD | 0.0% |
2018 Q2 | -994.32 Thousand AUD | 0.0% |
2018 FY | -2.49 Million AUD | -136.06% |
2017 Q2 | -502.1 Thousand AUD | 0.0% |
2017 FY | -1.05 Million AUD | 2.12% |
2017 Q4 | -555.77 Thousand AUD | 0.0% |
2016 Q2 | -577.21 Thousand AUD | 0.0% |
2016 FY | -1.08 Million AUD | 87.24% |
2016 Q4 | -503.56 Thousand AUD | 0.0% |
2015 FY | -8.47 Million AUD | -16.21% |
2015 Q4 | -5.78 Million AUD | 0.0% |
2015 Q2 | -2.68 Million AUD | 0.0% |
2014 Q4 | -4.03 Million AUD | 0.0% |
2014 Q2 | -3.25 Million AUD | 0.0% |
2014 FY | -7.28 Million AUD | -106.54% |
2013 Q3 | -882.27 Thousand AUD | 30.31% |
2013 Q2 | -1.26 Million AUD | 0.88% |
2013 FY | -3.52 Million AUD | 30.92% |
2013 Q1 | -1.27 Million AUD | 0.0% |
2013 Q4 | -2.26 Million AUD | -156.51% |
2012 Q1 | -1.85 Million AUD | 0.0% |
2012 Q4 | -1.27 Million AUD | 0.0% |
2012 FY | -5.1 Million AUD | 31.16% |
2012 Q2 | -1.27 Million AUD | 31.16% |
2012 Q3 | -1.27 Million AUD | 0.0% |
2011 Q4 | -1.85 Million AUD | 0.0% |
2011 Q1 | -1.88 Million AUD | 0.0% |
2011 Q2 | -1.85 Million AUD | 1.51% |
2011 Q3 | -1.85 Million AUD | 0.0% |
2011 FY | -7.42 Million AUD | 1.51% |
2010 Q3 | -1.88 Million AUD | 0.0% |
2010 FY | -7.53 Million AUD | 13.01% |
2010 Q1 | -2.16 Million AUD | 0.0% |
2010 Q2 | -1.88 Million AUD | 13.01% |
2010 Q4 | -1.88 Million AUD | 0.0% |
2009 Q1 | -1.83 Million AUD | 0.0% |
2009 FY | -8.66 Million AUD | -18.28% |
2009 Q4 | -2.16 Million AUD | 0.0% |
2009 Q2 | -2.16 Million AUD | -18.28% |
2009 Q3 | -2.16 Million AUD | 0.0% |
2008 FY | -7.32 Million AUD | 0.0% |
2008 Q1 | - AUD | 0.0% |
2008 Q3 | -1.83 Million AUD | 0.0% |
2008 Q2 | -1.83 Million AUD | 0.0% |
2008 Q4 | -1.83 Million AUD | 0.0% |
2007 FY | - AUD | 0.0% |
2007 Q4 | - AUD | 0.0% |
2007 Q3 | - AUD | 0.0% |
2007 Q2 | - AUD | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
AdAlta Limited | -5.38 Million AUD | 34.232% |
Acrux Limited | -5.8 Million AUD | 38.98% |
Actinogen Medical Limited | -13.04 Million AUD | 72.868% |
AnteoTech Limited | -8.88 Million AUD | 60.147% |
Argenica Therapeutics Limited | -5.47 Million AUD | 35.411% |
Arovella Therapeutics Limited | -8.74 Million AUD | 59.534% |
Anatara Lifesciences Ltd | -1.45 Million AUD | -143.87% |
Alterity Therapeutics Limited | -19.12 Million AUD | 81.493% |
Amplia Therapeutics Limited | -4.5 Million AUD | 21.413% |
Avecho Biotechnology Limited | -3.43 Million AUD | -2.985% |
Bio-Gene Technology Limited | -2.4 Million AUD | -46.903% |
Biome Australia Limited | -1.67 Million AUD | -111.9% |
Biotron Limited | -3.43 Million AUD | -2.986% |
Botanix Pharmaceuticals Limited | -13.86 Million AUD | 74.483% |
BTC Health Limited | 1.05 Million AUD | 435.373% |
Chimeric Therapeutics Limited | -12.52 Million AUD | 71.754% |
CSL Limited | 2.64 Billion AUD | 100.134% |
Clarity Pharmaceuticals Ltd | -42.32 Million AUD | 91.638% |
Clinuvel Pharmaceuticals Limited | 35.63 Million AUD | 109.931% |
Cynata Therapeutics Limited | -9.74 Million AUD | 63.681% |
Dimerix Limited | -17.07 Million AUD | 79.273% |
EZZ Life Science Holdings Limited | 6.96 Million AUD | 150.817% |
Hexima Limited | -933.87 Thousand AUD | -278.976% |
Island Pharmaceuticals Limited | -2.86 Million AUD | -23.56% |
Immuron Limited | -6.93 Million AUD | 48.981% |
Immutep Limited | -39.89 Million AUD | 91.129% |
Imugene Limited | -149.68 Million AUD | 97.636% |
Invex Therapeutics Ltd | -1.64 Million AUD | -115.564% |
Memphasys Limited | -4.44 Million AUD | 20.326% |
Nanollose Limited | -1.15 Million AUD | -206.008% |
Neuren Pharmaceuticals Limited | 157.08 Million AUD | 102.253% |
Noxopharm Limited | -3.57 Million AUD | 1.089% |
NeuroScientific Biopharmaceuticals Limited | 324.21 Thousand AUD | 1191.623% |
Nyrada Inc. | -1.38 Million AUD | -155.308% |
Orthocell Limited | -7.18 Million AUD | 50.715% |
PharmAust Limited | -9.03 Million AUD | 60.817% |
Paradigm Biopharmaceuticals Limited | -58.65 Million AUD | 93.966% |
Proteomics International Laboratories Limited | -6.37 Million AUD | 44.495% |
Prescient Therapeutics Limited | -8.23 Million AUD | 57.039% |
PYC Therapeutics Limited | -37.72 Million AUD | 90.619% |
Race Oncology Limited | -13.81 Million AUD | 74.39% |
Radiopharm Theranostics Limited | -47.94 Million AUD | 92.619% |
Recce Pharmaceuticals Ltd | -17.66 Million AUD | 79.961% |
Starpharma Holdings Limited | -8.16 Million AUD | 56.655% |
Telix Pharmaceuticals Limited | 5.21 Million AUD | 167.917% |
Tissue Repair Ltd | -4.13 Million AUD | 14.474% |
Zelira Therapeutics Limited | -36.56 Million AUD | 90.322% |